MR MRK Merck & Co., Inc. Loading... : Bullish and Bearish Analyst Opinions

Chip selloff and AI spending concerns drove a broad market decline, with the Nasdaq 100 falling 1.6% and Alphabet dropping 4.4% on reports its AI model is behind schedule, while TSMC's strong results failed to lift sentiment.

Merck received FDA approval for Lipfendra, the first once-daily oral PCSK9 inhibitor, with analysts expecting multi-billion-dollar sales potential.

Merck & Co. won regulatory approval for a pill version of a powerful cholesterol medication that Wall Street analysts have said could generate billions in annual sales.

Merck's first-of-its-kind cholesterol pill has been approved by regulators, ushering in a new wave of treatment according to the Wall Street Journal.

US pre-market movers report shows ASML up on earnings beat, PayPal surging on acquisition offer, and PNR falling after CFO resignation and weak preliminary results.

Merck announces its Phase 3 Keytruda trial successfully met the primary progression-free survival endpoint.

Berenberg raises Merck & Co's price target to $127 from $125, reflecting a modestly improved outlook for the pharmaceutical company.

Named as a potential ERAS acquirer with an existing clinical collaboration; previously ran a full process on RVMD but couldn't close.

US lawmakers have launched an investigation into the China drug trial activities of Merck & Co. and AbbVie.

U.S. House committee investigates AbbVie and Merck over China drug trials to determine if they fueled China's military capabilities

Pre-market movers include Apple and Google flat on UK CMA probe, CNXC plunging 24% on weak outlook, DLR falling 5% on data center deal, AVAV surging 28% on earnings beat, GMAB rising 8% on positive trial results, ABBV and MRK dipping on House investigation, and LCII up 7% on merger with Patrick Industries.

Own diversified basket across sectors.

Author notes health and biotech names like DHR and MRK have been outperforming as a hedge but does not state a personal position or forward call.

Merck receives European Commission approval for its Keytruda combination therapy in bladder cancer treatment.

The author presents a factual analysis of M&A activity in the biotech sector since Covid, noting that many large pharma companies have not yet engaged in significant deals, but does not express a personal position or forward-looking trade call.

Merck received approval in China for a lower respiratory tract infection treatment targeting infants and newborns.

The author maps out M&A scenarios in oncology but presents them as possibilities and research, not current positions or explicit trade calls.

Gilead and Merck report positive Phase 3 results for their once-weekly oral HIV treatment islatravir/lenacapavir, with primary efficacy endpoints met at week 48 in both ISLEND-1 and ISLEND-2 trials.

Merck will resolve most Gardasil lawsuits for approximately 50 million dollars.

The author warns that equity markets near all-time highs face multiple compression from rising real yields, consumer bifurcation, and $103bn in potential CTA selling, while Chinese AI models outpace U.S. peers and geopolitical risks remain fragile.

Traderstewie shares a list of upcoming earnings from Earnings Whispers for the week of April 27, 2026, but

Merck may drop further; buy cautiously.

The tweet presents a forward-looking call for a long position in Merck based on a bullish technical chart pattern anticipating an imminent breakout.

Jefferies analysts are bullish on Merck, raising their price target, implying expected upside from current levels.

The author questions the clinical efficacy and dose-response data of Merck's sotatercept, suggesting potential overvaluation.

MRK trades at a 33% P/E discount to its 5-year average, with a 19% FCF margin and 80 active Phase 3 trials. The market is over-discounting the 2028 Keytruda patent expiration and ignoring Merck's robust pipeline, recent M&A, and restructuring efforts. Buy MRK as a compelling value opportunity insulated by a strong pipeline and a 2.93% dividend yield. The pipeline and recent acquisitions fail to adequately replace the massive revenue drop-off when Keytruda exclusivity ends.

Cramer agreed with Bob Lang's analysis that it's time to buy big pharma names like Pfizer, Merck, and Bristol Myers for their dividends and safety in a potential slowdown. These companies have strong dividend yields (e.g., Pfizer 6.3%, Merck nearly 3%, Bristol Myers 4.3%), bullish technical indicators (money flow, cup-and-handle patterns), and are recession-resistant as medication demand is inelastic. LONG because they offer yield protection and potential capital appreciation in a potential economic slowdown, making them defensive plays. If the economy avoids a slowdown, these stocks might underperform growth sectors; drug pipeline setbacks could impact earnings.

"The Trump RX plan of course is developed by these private meetings with the pharma types... especially Merc and Eli Lily and J&J have been very effective at that." Companies that engage Trump privately and collectively can shape policy in their favor without triggering his public attacks. The pharmaceutical sector successfully used this playbook to navigate drug pricing policies, resulting in a plan that was much better for the industry than critics anticipated. LONG. These large pharma companies have proven they can manage political and regulatory risk under Trump by using private, collective influence to protect their margins. The presence of RFK Jr. in the administration is noted as a "pernicious problem" that could introduce unpredictable regulatory or narrative risks for the sector.

A corporate restructuring explicitly driven by "looming sales pressure" signals management's concern about future revenue headwinds for the core business.

HSBC's price target increase suggests a more bullish outlook on the stock, implying expected upside from current levels.